A review on the role of Siglec-7 in ovarian cancer and related molecular docking studies
| bracu.degree.level | Undergraduate | |
| bracu.type.group | Student Works | |
| datacite.rights | Open Access | |
| dc.contributor.advisor | Omer, Humair Bin Md. | |
| dc.contributor.author | Achol, Noshin Atia | |
| dc.contributor.department | School of Pharmacy | |
| dc.date.accessioned | 2025-09-08T08:56:15Z | |
| dc.date.available | 2025-09-08T08:56:15Z | |
| dc.date.copyright | 2025 | |
| dc.date.issued | 2025-08 | |
| dc.description | Cataloged from PDF version of thesis. | |
| dc.description | Includes bibliographical references (pages 28-33). | |
| dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2025. | en_US |
| dc.description.abstract | Ovarian cancer is one of the most lethal gynecological cancers in the world. Recent developments in immunology have revealed that ovarian cancer uses Siglec-7 protein. It is a sialic acid-binding immunoglobulin-like lectin that is expressed on natural killer cells. The pathophysiology of ovarian cancer and the potential of Siglec-7 as a therapeutic target are explored in this review. The focus is particularly on α-2,8-disialic acid motifs. This review also focuses on molecular docking studies in the literature concerning Siglec-7. Analysis of C9-modified sialosides have revealed enhanced hydrophobic interaction upon modifications with biphenyl and oxamido derivatives. A collection of new tailor-constructed sialic acid analogues with combined C4 azido, C9 aromatic, and triazole modifications are reviewed. A combination of functional group changes was made based on previous studies that showed chemical modifications with favorable results. A thorough approach for docking, receptor-ligand preparation is also carried out in this review. | en_US |
| dc.description.degree | Bachelor of Pharmacy | |
| dc.description.statementofresponsibility | Noshin Atia Achol | |
| dc.format.extent | 47 pages | |
| dc.identifier.other | ID 21346097 | |
| dc.identifier.uri | http://hdl.handle.net/10361/26682 | |
| dc.language.iso | en | en_US |
| dc.publisher | BRAC University | en_US |
| dc.rights | BRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
| dc.subject | Ovarian cancer | en_US |
| dc.subject | Siglec-7 | en_US |
| dc.subject | Sialic acid derivatives | en_US |
| dc.subject | Molecular docking | en_US |
| dc.subject | Gangliosides | en_US |
| dc.subject | Ovarian neoplasms | en_US |
| dc.subject | Drug design | en_US |
| dc.subject.lcsh | Drug development. | |
| dc.subject.lcsh | Ovaries--Cancer. | |
| dc.subject.lcsh | Lectins--Immunology--Congresses. | |
| dc.title | A review on the role of Siglec-7 in ovarian cancer and related molecular docking studies | en_US |
| dc.type | Thesis | en_US |